Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
BriaCell Therapeutics Corp. BCTX
$6.45
-$0.48 (-7.46%)
На 18:04, 12 мая 2023
Ранг: 4
Ключевые показатели
-
Marketcap
113436580.00000000
-
week52high
8.37
-
week52low
4.06
-
Revenue
0
-
P/E TTM
-3
-
Beta
1.67507200
-
EPS
-0.53000000
-
Last Dividend
0.00000000
-
Next Earnings Date
12 июн 2023 г. в 04:00
Описание компании
BriaCell Therapeutics Corp., a clinical stage immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to investigate the mechanism of action of novel off-the-shelf personalized therapeutics for cancer. The company is headquartered in West Vancouver, Canada.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bondarenko Jamieson | A | 169856 | 28000 | 28 дек 2022 г. |
| Williams William V. | A | 29802 | 2530 | 23 дек 2022 г. |
| Bondarenko Jamieson | A | 141856 | 22000 | 20 дек 2022 г. |
Новостная лента
BriaCell Therapeutics: Fast-Tracking High-Potential Breast Cancer Immunotherapy
Seeking Alpha
30 янв 2023 г. в 08:02
BriaCell Therapeutics aims to create cancer immunotherapy by irradiating and engineering existing cancer cells. Lead candidate Bria-IMT for breast cancer showed good tolerability and efficacy in 46 heavily pretreated patients so far.
BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium® December 6th and 7th
GlobeNewsWire
28 сент 2022 г. в 09:15
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that its lead product candidate, Bria-IMT™, will be featured in three posters during the 2022 San Antonio Breast Cancer Symposium® taking place December 6-10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.